Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss drugs Wegovy and Ozempic.
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company's diabetes and weight-loss drugs, including Ozempic and Wegovy.
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.S. government price controls, the Financial Times reported on Monday.
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The latest news from the Danish drug developer was not encouraging. Its experimental weight loss drug produced results, but also a set of side effects.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm's latest obesity treatment showed less effectiveness in higher doses.
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms and improved physical function.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Novo Nordisk shares drop more than 4% on disappointing obesity pill data
Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations.
Novo's Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
The blockbuster drug strengthens its case that obesity drugs have health benefits beyond weight-loss.
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's Wegovy in patients with an obesity-related heart condition, the Danish drugmaker said on Thursday.
